Starpharma Holdings Sustainability Profile
Starpharma Holdings Limited, headquartered in Australia, is a pioneering biotechnology company renowned for its innovative work in drug delivery and development. Founded in 1996, Starpharma has made significant strides in the pharmaceutical industry, particularly in the areas of dendrimer-based therapies and antiviral products. The company’s flagship product, VivaGel®, is a unique antiviral and antibacterial gel that has garnered attention for its efficacy in preventing sexually transmitted infections. Starpharma's commitment to research and development has positioned it as a leader in the biotech sector, with a strong focus on enhancing the safety and effectiveness of existing therapies. With a robust pipeline and strategic partnerships, Starpharma continues to expand its market presence, contributing to advancements in healthcare and improving patient outcomes globally.
DitchCarbon Score
How does Starpharma Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Starpharma Holdings's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Starpharma Holdings's reported carbon emissions
In 2025, Starpharma Holdings reported total carbon emissions of approximately 323,000 kg CO2e, a decrease from about 357,000 kg CO2e in 2024 and about 385,000 kg CO2e in 2023. The emissions data for 2022 indicates a total of approximately 442,350 kg CO2e, comprising about 25,670 kg CO2e from Scope 1 and about 416,680 kg CO2e from Scope 2. For 2021, the company recorded approximately 481,800 kg CO2e, with about 24,400 kg CO2e from Scope 1 and about 457,400 kg CO2e from Scope 2. Starpharma has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from any parent organisation, indicating that all reported figures are directly from Starpharma Holdings Limited. Overall, Starpharma is actively monitoring its carbon footprint, with a notable trend of decreasing emissions over the past few years, reflecting its commitment to improving environmental performance.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 24,400 | 00,000 | - | - | - |
| Scope 2 | 457,400 | 000,000 | - | - | - |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Starpharma Holdings's Industry?
How Carbon Intensive is Starpharma Holdings's Location?
Starpharma Holdings's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Starpharma Holdings has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
